Morphine sulfate and naltrexone hydrochloride extended-release capsules: Naltrexone release, pharmacodynamics, and tolerability

Pain Physician

Volumn 14, Issue 4, 2011, Pages 391-406

  Johnson, Franklin ^a   Setnik, Beatrice ^b  

^a ClinPharm PK Consulting LLC ^*  (United States)

^b PFIZER INC   (United States)

Author keywords

Chronic pain; Drug liking; Euphoria; Extended release opioids; Morphine; Naltrexone; Opioid withdrawal; Pharmacodynamics; Pharmacokinetics

Indexed keywords

MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE; NALTREXOL; NALTREXONE; NARCOTIC ANALGESIC AGENT; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EUPHORIA; FEMALE; HEADACHE; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MOOD DISORDER; NAUSEA; NONCARDIAC CHEST PAIN; PHARMACODYNAMICS; PRURITUS; QUANTITATIVE ANALYSIS; REVIEW; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUSTAINED DRUG RELEASE; VISUAL ANALOG SCALE; VOMITING; WITHDRAWAL SYNDROME;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; DRUG COMBINATIONS; HUMANS; MORPHINE; NALTREXONE; ROC CURVE;

EID: 79960879258     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauksop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C. Opioid treatment guidelines. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113-130.
2. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, Patel S, Manchikanti L. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008; 11:S5-S62.
3. Gourlay GK. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. Clin Pharmacokinet 1998; 35:173-190.
4. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: Pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001; 8:181-186.
5. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63:17-32.
6. Gibofsky A, Barkin RL. Chronic pain of osteoarthritis: Considerations for selecting an extended-release opioid analgesic. Am J Ther 2008; 15:241-255.
7. Nicholson B, Passik SD. Management of chronic noncancer pain in the primary care setting. South Med J 2007; 100:1028-1036.
8. Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 2006; 3:489-497.
9. Manchikanti L. National drug control policy and prescription drug abuse: Facts and fallacies. Pain Physician 2007; 10:399-424.
10. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007; 297:249-251.
11. Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007; 23:648-660.
12. Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, Carr DB, Cicero TJ, Gourlay D, Inciardi JA, Joranson DE, Kesslick J, Lande SD. Foundations of opioid risk management. Clin J Pain 2007; 23:103-118.
13. Gagnon AM, Kahan M, Srivastava A. Opioid use and abuse: Is there a problem? Clin J Pain 2007; 23:661-662.
14. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 2006; 81:103-107.
15. Gershell L, Goater JJ. Making gains in pain. Nat Rev Drug Discov 2006; 5:889-890.
16. Woolf CJ, Hashmi M. Use and abuse of opioid analgesics: Potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Invest Drugs 2004; 5:61-66.
17. Fudala PJ, Johnson RE. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006; 83 Suppl 1:S40-S47.
18. Wright C, Kramer ED, Zalman MA, Smith MY, Haddox JD. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend 2006; 83:S68-S76.
19. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: Who is the target? Expert Opin Investig Drugs 2009; 18:255-263.
20. Misra AL. Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone. In: Willette RE, Barnett G (eds). Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-Release Preparations. Rockville, MD: US Department of Health and Human Services (DHHS); 1981. NIDA Research Monograph 28, 132-146.
21. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, doseproportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 1984; 45:15-19.
22. Gold MS, Dackis CA, Pottash ALC, Sternbach HH, Annitto WJ. Naltrexone, opiate addiction, and endorphins. Med Res Rev 1982; 2:211-246.
23. Wong DF, Ye W, Zhou Y, Brasic J, Alexander M, Nanadi A, Lorenz T, Tollefson G. In vivo human opiate receptor occupancy of naltrexone: A dose-response analysis. Abstract presented at the 36th Annual Meeting of the Society for Neuroscience; October 14-18, 2006; Atlanta, GA.
24. Kaiko RF, Grandy RP, Reder RF, Goldenheim PD, Sackler RS. A bioequivalence study of oral controlled-release morphine using naltrexone blockade. J Clin Pharmacol 1995; 35:499-504.
25. Gonzalez J, Brogden RN. Naltrexone: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35:192-213.
26. Verebey K. The clinical pharmacology of naltrexone: Pharmacology and pharmacodynamics. In: Willette RE and Barnett G. Naltrexone Pharmacochemistry and Sustained Release Preparations. Bethesda, MD: National Institute on Drug Abuse; 1980. Naltrexone: Research Monograph 28, 147-158.
27. Verebey K, Volavka J, Mule SJ, Resnick RB. Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 1976; 20:315-328.
28. Embeda [package insert]. Bristol, TN: King Pharmaceuticals, Inc; June 2009.
29. Johnson FK, Stark JG, Bieberdorf FA, Stauffer J. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: A single-dose, randomizedsequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther 2010; 32:1149-1164.
30. Johnson F, Sun S, Stauffer J, Wagner G. Morphine release profile in a formulation containing polymer-coated extendedrelease morphine sulfate plus sequestered naltrexone [abstract]. J Pain 2008; (Abstract 757):S40.
31. Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: Pharmacokinetics, efficacy, and safety. J Pain 2010; 11:303-311.
32. Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009; 29:777-790.
33. Lipman AG, Jackson KC II. Opioid pharmacotherapy. In: Warfield CA, Bajwa ZH (eds). Principles and Practices of Pain Medicine 2nd ed. McGraw-Hill, New York, NY, 2004, pp 583-600.
34. Webster LR, Brewer R, Wang C, Sekora D, Johnson F, Morris D, Stauffer J. Longterm safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage 2010; 40:734-746.
35. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. Accessed Aug. 12, 2010. www.fda.gov. March 2003; Revision 1. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf
36. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: statistical approaches to establishing bioequivalence. Accessed Aug. 12, 2010. www.fda.gov. January 2001. www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf
37. Cole JO, Orzack MH, Beake B, Bird M, Bar-Tal Y. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982; 43:69-74.
38. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003; 35:253-259.
39. ReVia [package insert]. Montvale, NJ: Barr Pharmaceuticals Inc.; July 2002.
40. Data on File. Study number: ALOKNT-302. Alpharma Pharmaceuticals LLC, a wholly owned subsidiary of King Pharmaceuticals, Inc, Bridgewater, NJ, which was acquired by Pfizer Inc in March 2011.
41. Johnson F, Stauffer J. Pharmacokinetics, drug-liking/euphoria, and long-term study of morphine sulfate and naltrexone hydrochloride extended release capsules. Poster presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 18-21, 2009; National Harbor, MD.
42. Data on File. Study number: ALO-01-07-205. Alpharma Pharmaceuticals LLC, a wholly owned subsidiary of King Pharmaceuticals, Inc, Bridgewater, NJ, which was acquired by Pfizer Inc in March 2011.
43. Alpharma Pharmaceuticals LLC. ALO-01 (morphine sulfate extended-release with sequestered naltrexone hydrochloride capsules) for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time: NDA open session briefing package. NDA-22-321. Meeting of the Anesthetic and Life Support Drugs Advisory Committee. FDA. gov. November 14, 2008. Accessed Oct. 21, 2010. www.fda.gov/ohrms/dockets/AC/08/briefing/2008-4395b2-02-ALPHARMA. pdf
44. Johnson F, Manning D, Wang C, Stauffer J. Evaluation of naltrexone concentrations following dosing with ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules for 1 year in patients with chronic pain. Poster presented at the 71st Annual Meeting of The College on Problems Drug Dependence; June 20-25, 2009; Reno, NV.
45. Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended-release capsules in patients with chronic osteoarthritis pain. Postgrad Med 2010; 122:112-128.
46. Johnson F, Ciric S, Boudriau S, Swearingen D, Stauffer J. Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. Adv Ther 2010; 27:846-858.
47. Johnson FK, Ciric S, Boudriau S, Kisicki J, Stauffer J. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol In press.
48. KADIAN CII Capsules [package insert]. Morristown, NJ: Actavis Kadian LLC; February 2010.
49. Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced non-dependent male opioid users. Drugs R D 2011, in press.
50. Jang DH, Robe JC, Hoffman RS. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med 2010; 55:303-304.
51. Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature. J Opioid Manag 2010; 6:300-303.
52. Data on File. Study number: ALO-01-07-104. Alpharma Pharmaceuticals LLC, a wholly owned subsidiary of King Pharmaceuticals, Inc, Bridgewater, NJ, which was acquired by Pfizer Inc in March 2011.